Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (121-130 of 574) with videos related to

Pageof 58
Sort By:
American Journal of Clinical Oncology|March 23, 2011
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot studyAnne M Horgan, Natasha B Leighl, Linda Coate, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2012
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancerGeoffrey Liu, D Cheng, K Ding, et al.
The Oncologist|October 22, 2025
Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN StudyGeoffrey Liu, Benjamin J Solomon, Julien Mazieres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patientsRebecca Suk, Sarada Gurubhagavatula, Sohee Park, et al.
Cancer|November 10, 2004
The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphismsGeoffrey Liu, Wei Zhou, Sohee Park, et al.
Cancer|January 22, 2008
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinomaPaul Wheatley-Price, Kofi Asomaning, Amy Reid, et al.
Lung Cancer (Amsterdam, Netherlands)|July 8, 2020
Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method studyJi Hyun Sung, M Catherine Brown, Andrea Perez-Cosio, et al.
Journal of Thoracic Disease|July 10, 2020
Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancerMike Sung, Alona Zer, Preet Walia, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
No association between the p21 codon 31 serine-arginine polymorphism and lung cancer riskLi Su, Geoffrey Liu, Wei Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2006
Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patientsWei Zhou, Rebecca Suk Heist, Geoffrey Liu, et al.
Pageof 58

Showing results (121-130 of 574) with videos related to

Sort By:
Pageof 58
American Journal of Clinical Oncology|March 23, 2011
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot studyAnne M Horgan, Natasha B Leighl, Linda Coate, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2012
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancerGeoffrey Liu, D Cheng, K Ding, et al.
The Oncologist|October 22, 2025
Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN StudyGeoffrey Liu, Benjamin J Solomon, Julien Mazieres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patientsRebecca Suk, Sarada Gurubhagavatula, Sohee Park, et al.
Cancer|November 10, 2004
The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphismsGeoffrey Liu, Wei Zhou, Sohee Park, et al.
Cancer|January 22, 2008
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinomaPaul Wheatley-Price, Kofi Asomaning, Amy Reid, et al.
Lung Cancer (Amsterdam, Netherlands)|July 8, 2020
Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method studyJi Hyun Sung, M Catherine Brown, Andrea Perez-Cosio, et al.
Journal of Thoracic Disease|July 10, 2020
Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancerMike Sung, Alona Zer, Preet Walia, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
No association between the p21 codon 31 serine-arginine polymorphism and lung cancer riskLi Su, Geoffrey Liu, Wei Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2006
Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patientsWei Zhou, Rebecca Suk Heist, Geoffrey Liu, et al.
Pageof 58